

**ABSTRACT OF THE DISCLOSURE**

A method of combating movement disorder in a patient experiencing or susceptible to same, by administering to the patient an effective amount of a neurotransmission modulating composition including a 5HT antagonist and/or  $\alpha_2$  antagonist. The antagonist may for example include a piperazinoazepine compound such as mirtazapine that is a receptor antagonist for 5HT<sub>2/3</sub> and  $\alpha_2$  receptors.